## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:	Abbott GmbH & Co. KG	JC20 Rec'd PCT/PTO	11 OCT 2005
Serial No.:		Group Art Unit:	
Filed:	October 11, 2005		
For:	)		
Examiner:	)		

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents Washington, D.C. 20231

Sir:

Attached Form PTO/SB/08A lists references which may be considered to be material to the above-identified application by the Patent Examiner. Copies of the references are enclosed. Entry into the record is respectfully requested.

Respectfully submitted

Martin L. Katz, Reg. No. 25,011

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER Citicorp Center, Suite 3800 500 West Madison Street Chicago, Illinois 60661-2511 312/876-1800

## **CERTIFICATE OF MAILING**

Stephanie Frain

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on October 11, 2005.

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

Application Number Substitute for form 1449A/PTO Filing Date October 11, 2005 INFORMATION DISCLOSURE First Named Inventor Wilfried Braje, et al. STATEMENT BY APPLICANT **Group Art Unit** (Use as many sheets as necessary) **Examiner Name** Sheet of 2 Attorney Docket No. ABB10043P0013US

				U.S. PATENT DO	CUMENTS	
Examiner Cite Initials* No.	Cite			Publication Date	Name of Patentee or	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	No.'			MM-DD-YYYY	Applicant of Cited Document	
		US-	6,472,392 B1	10/29/2002	Starck, et al.	
		US-	6,090,807	07/18/2000	Hellendahl, et al.	
		US-	5,958,923	09/28/1999	Hellendahl, et al.	
		US-	4,577,020	03/18/1986	Gall	
		US-	6,342,604 B1	01/29/2002	Hellendahl, et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Cite Initials' No.1	Cite	Foreign Patent Document	Publication Date		of Patentee or	Pages, Columns, Lines, Where Relevant Passages		
	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-VVVV Applic		eant of Cited ocument	or Relevant Figures Appear	J.e		
		WO 03/002543 A1	01/09/2003	Abbott Laboratories				
		WO 2004/058265 A1	07/15/2004	BIOFOCUS PLC				
				<u> </u>	<del>r</del>			
Examiner S	ignature				Date Conside	ered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 'Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. 'Skind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16. if possible. 'Applicant is to place a checkmark here if English language Translation is attached.

Standards ST.16, if possible. <sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## JC20 Rec'd PCT/PTO 11 OCT 2005

Comparable to Form PTO/SB/08A (08-03 Approved for use through 0731/2006 OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwoi	k Reduction A	ict of 1995, no pe	rsons are req	uired to respond to a collection of	information unless it displays a valid OMB control number
Substitute for form 1449A/PTO			Application Number	10/552842	
				Filing Date	October 11, 2005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Wilfried Braje, et al.
				Group Art Unit	
(Use as many sho	eets as neces	isary)	Examiner Name		
Sheet	2	of	2	Attorney Docket No.	ABB10043P0013US

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cit e No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
		J. C. SCHWARTZ, ET AL. The DopamineD <sup>3</sup> Receptor as a Target for Antipsychotics pp. 135-144						
		S. M. BROMIDGE, ET AL. 5-Chloro-N-(4-methoxy-3piperazin-1-yl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT6 Receptor Antagonist pp.202-205						
		S. M. BROMIDGE, ET AL. Novel (4-Piperazin-1-ylquinolin-6-yl) Arylsulfonamides with Hight Affinity and Selectivity for the 5-HT6 Receptor pp. 2843-2846						
		B. WILLECOMME Recherches Dans La Serie De La Piperazine pp. 405-428						
		J. N. JOYCE Dopamine D <sup>3</sup> receptor a s a therapeutic target for antipsychotic and antiparkinsonian drugs pp. 232-259						
	-	P. SOKOLOFF, ET AL. Localization and Function of the D <sup>3</sup> Dopamine Receiptor pp.224-230						
		P. SOKOLOFF, ET AL. Molecular cloning and characterization of a novel dopamine receptor (D³) as a target for neuroleptic pp. 146-151						
		M. DOOLEY, ET AL. Pramipexole A Review of its Use in the Management of Early and Advanced Parkinson's Disease pp. 495-513						
Examiner Sigr	nature	Date Considered						

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.